A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication

Atherosclerosis

Volumn 229, Issue 1, 2013, Pages 1-9

  Delaney, Christopher L ^a   Spark, J Ian ^a   Thomas, Jolene ^a   Wong, Yew Toh ^a   Chan, Lok Tsung ^a   Miller, Michelle D ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

Carnitine; Peripheral arterial disease; Walking performance

Indexed keywords

ACETYLCARNITINE; CARNITINE; PLACEBO; PROPIONYLCARNITINE;

CLINICAL EVALUATION; COCHRANE LIBRARY; CONSERVATIVE TREATMENT; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; INTERMITTENT CLAUDICATION; JADAD SCALE; MEDLINE; META ANALYSIS; PAIN ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACODYNAMICS; PRETEST POSTTEST DESIGN; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; SYSTEMATIC REVIEW; TREADMILL EXERCISE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WALKING; WALKING SPEED;

CARNITINE; HUMANS; INTERMITTENT CLAUDICATION; VITAMIN B COMPLEX; WALKING;

EID: 84879409393     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.03.004     Document Type: Review

References (33)

1. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G.R. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007, 33(Supplement 1):S1-S75.
2. Schainfeld R.M. Management of peripheral arterial disease and intermittent claudication. JAm Board Fam Prac 2001, 14:443-450.
3. Hirsch A.T., Haskal Z.J., Hertzer N.R., et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation 2006, 113(11):e463-e465.
4. Watson L., Ellis B., Leng G.C. Exercise for intermittent claudication. Cochrane Database Syst Rev 2008, (4). Art. No.: CD000990. 10.1002/14651858.CD000990.pub2.
5. Robless P., Mikhailidis D.P., Stansby G.P. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008, (1). Art. No.: CD003748. 10.1002/14651858.CD003748.pub3.
6. Mingorance C., Rodriguez-Rodriguez R., Justo M.L., Herrera M.D., Alvarez de Sotomayor M. Pharmacological effects and clinical applications of propionyl-L-carnitine. Nutr Rev 2011, 69(5):279-290.
7. Brevetti G., Angelini C., Rosa M., et al. Muscle carnitine deficiency in patients with severe peripheral vascular disease. Circulation 1991, 84:1490-1495.
8. Hiatt W.R. Carnitine and peripheral arterial disease. Ann N Y Acad Sci 2004, 1033:92-98.
9. Hiatt W.R., Wolfel E.E., Regensteiner J.G., Brass E.P. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. JAppl Physiol 1992, 73(1):346-353.
10. Brevetti G., Perna S., Sabba C., Martone V.D., Condorelli M. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. JAm Coll Cardiol 1995, 26(6):1411-1416.
11. Vita J.A., Hamburg N.M. Does endothelial dysfunction contribute to the clinical status of patients with peripheral arterial disease?. Can J Cardiol 2010, 26(Suppl. A):45A-50A.
12. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Contr Clin Trial 1996, 17(1):1-12.
13. Taylor D.J., Amato A., Hands L.J., et al. Changes in energy metabolism of calf muscle in patients with intermittent claudication assessed by 31P magnetic resonance spectroscopy: a phase II open study. Vasc Med 1996, 1(4):241-245.
14. Barker G.A., Green S., Askew C.D., Green A.A., Walker P.J. Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. Med Sci Sports Exerc 2001, 33(9):1415-1422.
15. Ragozzino G., Mattera E., Madrid E., et al. Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial. Drugs Res Develop 2004, 5(4):185-190.
16. Riccioni C., Sarcinella R., Palermo G., et al. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II. Int Angiol 2008, 27(3):253-259.
17. Allegra C., Antignani P.L., Schachter I., Koverech A., Messano M., Vermani A. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease. Ann Vasc Surg 2008, 22(4):552-558.
18. Coto V., D'Alessandro L., Grattarola G., et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs Exp Clin Res 1992, 18(1):29-36.
19. Brevetti G., Diehm C., Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. JAm Coll Cardiol 1999, 34(5):1618-1624.
20. Dal Lago A., De Martini D., Flore R., et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs Exp Clin Res 1999, 25(1):29-36.
21. Hiatt W.R., Regensteiner J.G., Creager M.A., et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001, 110(8):616-622.
22. Andreozzi G.M., Leone A., Laudani R., Martin R., Deinit G., Cataldi V. Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiol 2008, 59(1):84-89.
23. Hiatt W.R., Creager M.A., Amato A., Brass E.P. Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease. JCardiopulm Rehabil Prev 2011, 31(2):125-132.
24. Golderberg N.A., Krantz M.J., Hiatt W.R. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial. Vasc Med 2012, 17(3):145-154.
25. Brevetti G., Chiarello M., Ferulano G., et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 1988, 77(4):767-773.
26. Brevetti G., Perna S., Sabba C., et al. Superiority of L-propionylcarnitine vs. L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J 1992, 13(2):251-255.
27. Loffredo L., Pignatelli P., Cangemi R., et al. Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: effect of an antioxidant treatment. JVasc Surg 2006, 44(3):525-530.
28. Arsenian M.A. Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis 1997, 40(3):265-286.
29. Rebouche C.J. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci 2004, 1033:30-41.
30. Brass E.P. Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients. Clin Ther 1995, 17(2):176-185.
31. Evans A.M., Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharm 2003, 42(11):941-967.
32. Ferrari R., Merli E., Cicchitelli G., Mele D., Fucili A., Ceconi C. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 2004, 1033:79-91.
33. Pace S., Longo A., Toon S., Rolan P., Evans A.M. Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsoprtion. Br J Clin Pharmacol 2000, 50(5):441-448.